Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.77 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340843 | 0.87 | MIF (1.00) | MIFGRIN2BTAAR1IDO1HTR2A | |
| SCHEMBL6660390 | 0.84 | MIF (0.67) | MIFGRIN2BTAAR1IDO1HTR2A | |
| SCHEMBL2489084 | 0.80 | MIF (0.71) | MIFGRIN2BTAAR1IDO1HTR2A | |
| SCHEMBL7079916 | 0.80 | MIF (0.71) | MIFGRIN2BTAAR1IDO1HTR2A | |
| SCHEMBL6657463 | 0.76 | HTR3E (0.49) | MIFGRIN2BTAAR1IDO1ALDH1A1 | |
| SCHEMBL43367 | 0.74 | MIF (0.62) | MIFGRIN2BTAAR1IDO1HTR2A | |
| SCHEMBL3636560 | 0.74 | MIF (0.62) | MIFTAAR1IDO1HTR2AHTR2B | |
| SCHEMBL1145488 | 0.71 | TAAR1 (0.60) | MIFGRIN2BTAAR1IDO1HTR2A | |
| SCHEMBL8069977 | 0.71 | TAAR1 (0.60) | MIFGRIN2BTAAR1IDO1HTR2A | |
| SCHEMBL5103155 | 0.70 | TAAR1 (0.64) | MIFGRIN2BTAAR1IDO1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320521-B1 | 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY DERIVATIVES OF CYCLOPENTYL-HEPTAN(EN)OIC ACID AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20020058692-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY COMPOUNDS AS THERAPEUTIC AGENTS | ALLERGAN SALES, INC. | 2002-05-16 | — | — | US | disclosed |
| US-6380251-B1 | THERAPY OF OCULAR HYPERTENSION WHICH COMPRISES ADMINISTERING CYCLOPENTANE HEPTAN(ENE)OIC ACID OR ITS 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY DERIVATIVES | ALLERGAN SALES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6291522-B1 | OCULAR HYPOTENSIVES. | ALLERGAN SALES, INC. | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058692-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY COMPOUNDS AS THERAPEUTIC AGENTS | OXER1, ENY2, CYP8B1 | MIF 2729/4885GRIN2B 2698/4885TAAR1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.